pharmaphorum

FDA delays decision on Sanofi's subcutaneous Sarclisa

The FDA has extended its review of a new subcutaneous formulation of Sanofi's multiple myeloma therapy Sarclisa – which has long played second fiddle to Johnson & Johnson's blockbuster rival Darzalex ...
SciELO

Reinforcement of the pelvic diaphragm using a purse-string suture in dogs: description of technique

Recurrence of perineal hernias is frequent, and is associated to poor identification of anatomical structures during surgery, inadequate suture placement, and failure of physical support of the pelvic ...
Pharm Exec

FDA Rejects AstraZeneca’s Application for Subcutaneous Indication of Saphnelo

The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive clinical trial results. The subcutaneous formulation allows self-administration, ...
ascopubs.org

Subcutaneous Immunotherapy in Cancer: Where We Are Now, What It Changes, and What to Watch Next

Subcutaneous (SC) formulations of monoclonal antibodies are rapidly transforming the delivery of cancer immunotherapy. Designed to replace or complement intravenous (IV) administration, SC delivery ...
ascopubs.org

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary ...

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...
Traders Magazine

FINRA Approves Overhaul of Pattern Day Trading Rules, Opens Doors for Smaller Investors

The Financial Industry Regulatory Authority (FINRA)’s Board of Governors has approved a major overhaul of its pattern day trading (PDT) rules, marking a critical shift in how active retail trading ...
Healio

FDA approves Tremfya for subcutaneous induction in adults with ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...
Medscape

FDA OK’s Subcutaneous Pembrolizumab for Solid Tumors

The US FDA has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck), a subcutaneous version of the intravenous formulation of Keytruda, for adults and children aged 12 years ...
FiercePharma

Merck scores FDA approval for subcutaneous Keytruda, securing potential blockbuster protection

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.
Medscape

FDA OKs Subcutaneous Lecanemab Maintenance Dosing for Early AD

The FDA has approved a subcutaneous formulation of lecanemab (Leqembi Iqlik, Eisai/Biogen) for maintenance dosing in patients with Alzheimer’s disease (AD) with mild cognitive impairment (MCI) or mild ...
MedPage Today

Subcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New Data

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, ...
The American Journal of Managed Care

Training Nurses for Subcutaneous Delivery

Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer ...